* Allelix Biopharmaceuticals Inc., of Toronto, said it willreceive up to $4.4 million from the Canadian-basedNeuroscience Partners Limited Partnership to conductresearch based on discoveries originating from Canada'sNeuroScience Network, which is a collaboration of 200scientists at 18 Canadian universities and institutions.Neuroscience Partners is a fund managed by MDS HealthVentures Capital Corp., of Toronto.

* Aronex Pharmaceuticals Inc., of The Woodlands,Texas, is telling shareholders it intends to redeemwarrants issued in connection with last month's mergerwith Oncologix Inc. Shareholders will have until Dec. 28,1995, to exercise the warrant. If all are exercised Aronexwould get about $10.8 million.

* CytRx Corp., of Atlanta, said its board of directorsauthorized repurchase of up to 5 million shares of CytRxcommon stock. The company said it made the movebecause it believed the stock was undervalued.

* Gensia Inc., of San Diego, submitted an amendment toits new drug application for the GENesa System, whichwas deemed not approvable in April 1995 for use indiagnosis of coronary artery disease.

* MGI Pharma Inc., of Minneapolis, entered into anagreement giving Japan-based Dainippon Pharmaceu-tical Co. Ltd. exclusive rights in Japan to its acylfulvenes,which are a family of cancer compounds completingpreclinical studies. MGI could receive up to $12 millionin precommercial milestones.

* Neurobiological Technologies Inc., of Richmond,Calif., said a Phase II pilot study of Dynorphin A, anatural peptide, for relieving pain showed the drug waswell-tolerated. Based on the results the company plans toconduct a larger Phase II trial of Dynorphin A as anadjunct to morphine for post-surgical pain.

* Receptagen Ltd., of Vancouver, Canada, and formershareholders of Ryan Pharmaceuticals Inc., of Bellevue,Wash., are involved in a court dispute over royaltypayments for Coenzyme Q10. Receptagen, whichacquired Ryan in January 1994, sued the formershareholders, saying it agreed only to provide royalties of5 percent on net sales of the drug for AIDS symptoms,not for other indications.

* Rhone-Poulenc Rorer Inc., of Collegeville, Pa. said itreceived an "approvable" letter from the FDA forTaxotere, an anticancer drug aimed at treating metastaticbreast cancer. The FDA's Oncologic Drugs AdvisoryCommittee recommended approval of Taxotere Oct. 17,1995. (See BioWorld Today, Oct. 18, 1995, p.1.)

* T Cell Sciences Inc., of Needham, Mass., said Phase Itrials of TP10, a soluble form of complement receptor 1,showed the drug was well tolerated in treatment ofpatients at risk of adult respiratory distress syndrome. Thedrug also is being tested in Phase I studies for reperfusioninjury.

* Teva Pharmaceutical Industries Ltd., of Jerusalem, saidthe FDA accepted for review the company's NDA forCopaxone (copolymer-1), which is a treatment formultiple sclerosis.

* The Liposome Co. Inc., of Princeton, N.J., said theSpanish Health Ministry granted market approval forAbelcet, the company's amphotericin B lipid complex.The drug will be marketed in Spain for serious fungalinfections in patients who failed to respond toconventional treatments, such as amphotericin B alone.Abelcet also is approved in the U.K. and Luxembourg.

* Xoma Corp., of Berkeley, Calif., said it scientistsidentified potential fungicidal peptides derived from thebactericidal permeability-increasing protein (BPI), whichis a human protein found in neutrophils and linked to theimmune system. Xoma has been studying BPI for its drugactivity against gram-negative bacteria.

(c) 1997 American Health Consultants. All rights reserved.